Daniel Young, MD
Hospitalist · Fenton, MONPI 1184742520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $624 and has fallen 53.5% since, to $291 in 2025. Among hospitalist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$282
- Nxstage Medical, Inc.$221
- Boehringer Ingelheim$148
- Mallinckrodt Enterprises LLC$120
- Fresenius USA Marketing, Inc.$103
- Amgen$93
- plus $521 from 13 others
What the payments were for
- Food & beverage$1,38493%
- Education$1037%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $282 |
| Nxstage Medical, Inc. | 1 | $221 |
| Boehringer Ingelheim | 2 | $148 |
| Mallinckrodt Enterprises LLC | 2 | $120 |
| Fresenius USA Marketing, Inc. | 4 | $103 |
| Amgen(2 entities) | 5 | $93 |
| Novartis | 3 | $69 |
| Novo Nordisk | 3 | $68 |
| Vifor Pharma, Inc. | 4 | $61 |
| Travere Therapeutics, Inc. | 4 | $57 |
| Bayer | 3 | $57 |
| GSK | 2 | $45 |
| Calliditas Therapeutics US Inc. | 1 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Vantive US Healthcare LLC | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$221
- JARDIANCE$125
- FARXIGA$121
How this compares
$1,487 in reported general payments places this provider in the 95th percentile of 712 hospitalist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 12 | $36,512 |
| JardianceEmpagliflozin | 31 | $27,809 |
| FarxigaDapagliflozin Propanediol | 16 | $12,193 |
| Sevelamer Carbonate | 56 | $9,466 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $8,596 |
| Calcium Acetate | 24 | $1,533 |
| Torsemide | 36 | $1,129 |
| Doxazosin Mesylate | 34 | $695 |
| Furosemide | 69 | $545 |
| Hydralazine Hcl | 30 | $353 |
| Amlodipine Besylate | 100 | $347 |
| Tamsulosin Hcl | 24 | $345 |
| Losartan Potassium | 59 | $338 |
| Potassium Chloride | 15 | $314 |
| Pantoprazole Sodium | 28 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $103 | $36,51212 claims |
| Boehringer IngelheimJardiance | $148 | $27,80931 claims |
| AstraZenecaFarxiga, Lokelma | $282 | $20,78927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 hospitalist providers in Missouri.
Other hospitalist in Fenton
- Mir ZulqarnainKansas City$161K
- Gian MusarraSaint Louis$25K
- Ghassan DaherSaint Louis$23K
- Marsha SchulteSaint Louis$23K
- Ijeoma NwelueSaint Louis$12K
- Karan MohanSt. Joseph$6K
- Aniesh BobbaColumbia$6K
- Arun MannemSaint Louis$6K
- Vasanthan KuppuswamySaint Louis$5K
- Yamuna KondapallySaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.